Effects of chronic renal failure on brain drug transporters in rats

Drug Metabolism and Disposition

Volumn 40, Issue 1, 2012, Pages 39-46

  Naud, Judith ^a,b   Laurin, Louis Philippe ^a   Michaud, Josée ^a,b   Beauchemin, Stéphanie ^a   Leblond, Francois A ^a   Pichette, Vincent ^a,b  

^a UNIVERSITY OF MONTREAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER RESISTANCE PROTEIN; DIGOXIN; DOXORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 2; MULTIDRUG RESISTANCE PROTEIN 4; MULTIDRUG RESISTANCE PROTEIN 5; ORGANIC ANION TRANSPORTER; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 3; PENICILLIN G; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; BLOOD BRAIN BARRIER; BRAIN BIOPSY; BRAIN REGION; CHRONIC KIDNEY FAILURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACCUMULATION; DRUG PENETRATION; ENDOTHELIUM CELL; EXPERIMENTAL MODEL; IN VIVO STUDY; INCUBATION TIME; ISOTOPE LABELING; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANIMALS; BIOLOGICAL TRANSPORT, ACTIVE; BLOOD-BRAIN BARRIER; BRAIN; CELLS, CULTURED; KIDNEY FAILURE, CHRONIC; MALE; MEMBRANE TRANSPORT PROTEINS; PHARMACEUTICAL PREPARATIONS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84455163215     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.111.041145     Document Type: Article

References (54)

1. Akahoshi T, Kobayashi N, Hosaka S, Sekiyama N, Wada C, and Kondo H (1995) In-vivo induction of monocyte chemotactic and activating factor in patients with chronic renal failure. Nephrol Dial Transplant 10:2244-2249. (Pubitemid 26033437)
2. Alpay H, Altun O, and Biyikli NK (2004) Cefepime-induced non-convulsive status epilepticus in a peritoneal dialysis patient. Pediatr Nephrol 19:445-447. (Pubitemid 38477411)
3. Booher J and Sensenbrenner M (1972) Growth and cultivation of dissociated neurons and glial cells from embryonic chick, rat and human brain in flask cultures. Neurobiology 2:97-105.
4. Chan LM, Lowes S, and Hirst BH (2004) The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur J Pharm Sci 21:25-51. (Pubitemid 38050202)
5. Chatellier D, Jourdain M, Mangalaboyi J, Ader F, Chopin C, Derambure P, and Fourrier F (2002) Cefepime-induced neurotoxicity: an underestimated complication of antibiotherapy in patients with acute renal failure. Intensive Care Med 28:214-217. (Pubitemid 34293837)
6. Choi MK, Kim H, Han YH, Song IS, and Shim CK (2009) Involvement of Mrp2/MRP2 in the species different excretion route of benzylpenicillin between rat and human. Xenobiotica 39:171-181.
7. Chow EC, Sun H, Khan AA, Groothuis GM, and Pang KS (2010) Effects of 1alpha,25-dihydroxyvitamin D3 on transporters and enzymes of the rat intestine and kidney in vivo. Biopharm Drug Dispos 31:91-108.
8. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, and Sugiyama Y (2007) Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol 71:1591-1597. (Pubitemid 47010912)
9. Deeken JF and Löscher W (2007) The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin Cancer Res 13:1663-1674. (Pubitemid 46952931)
10. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, and Sugiyama Y (2004) Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65:162-174. (Pubitemid 38037501)
11. Deguchi T, Isozaki K, Yousuke K, Terasaki T, and Otagiri M (2006) Involvement of organic anion transporters in the efflux of uremic toxins across the blood-brain barrier. J Neurochem 96:1051-1059.
12. Eyal S, Hsiao P, and Unadkat JD (2009) Drug interactions at the blood-brain barrier: fact or fantasy? Pharmacol Ther 123:80-104.
13. Ferrara N, Abete P, Giordano M, Ferrara P, Carnovale V, Leosco D, Beneduce F, Ciarambino T, Varricchio M, and Rengo F (2003) Neurotoxicity induced by Cefepime in a very old hemodialysis patient. Clin Nephrol 59:388-390. (Pubitemid 36592216)
14. Fishman RA (1966) Blood-brain and CSF barriers to penicillin and related organic acids. Arch Neurol 15:113-124.
15. Goralski KB, Hartmann G, Piquette-Miller M, and Renton KW (2003) Downregulation of mdr1a expression in the brain and liver during CNS inflammation alters the in vivo disposition of digoxin. Br J Pharmacol 139:35-48. (Pubitemid 36645306)
16. Hendrikse NH, Schinkel AH, de Vries EG, Fluks E, Van der Graaf WT, Willemsen AT, Vaalburg W, and Franssen EJ (1998) Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br J Pharmacol 124:1413-1418. (Pubitemid 28360563)
17. Higuchi T, Yamamoto C, Kuno T, Mizuno M, Takahashi S, and Kanmatsuse K (1997) Increased production of interleukin-1beta and interleukin-1 receptor antagonist by peripheral blood mononuclear cells in undialyzed chronic renal failure. Nephron 76:26-31. (Pubitemid 27199035)
18. Hsieh YJ, Chang CH, Huang SP, Lin CW, Wang MN, Wu YT, Chen YJ, and Tsai TH (2008) Effect of cyclosporin A on the brain regional distribution of doxorubicin in rats. Int J Pharm 350:265-271.
19. Huang ZH, Murakami T, Okochi A, Yumoto R, Nagai J, and Takano M (2000) Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol 406:453-460.
20. Kikuchi R, Kusuhara H, Sugiyama D, and Sugiyama Y (2003) Contribution of organic anion transporter 3 (Slc22a8) to the elimination of p-aminohippuric acid and benzylpenicillin across the blood-brain barrier. J Pharmacol Exp Ther 306:51-58. (Pubitemid 36734356)
21. Kusuhara H and Sugiyama Y (2005) Active efflux across the blood-brain barrier: role of the solute carrier family. NeuroRx 2:73-85. (Pubitemid 40128028)
22. Laouari D, Yang R, Veau C, Blanke I, and Friedlander G (2001) Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol 280:F636-F645.
23. Leblond F, Guévin C, Demers C, Pellerin I, Gascon-Barré M, and Pichette V (2001) Down-regulation of hepatic cytochrome P450 in chronic renal failure. J Am Soc Nephrol 12:326-332. (Pubitemid 32116374)
24. Leblond FA, Petrucci M, Dubé P, Bernier G, Bonnardeaux A, and Pichette V (2002) Downregulation of intestinal cytochrome p450 in chronic renal failure. J Am Soc Nephrol 13:1579-1585. (Pubitemid 34579247)
25. Livak KJ and Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
26. Löscher W and Potschka H (2005a) Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98. (Pubitemid 40128029)
27. Löscher W and Potschka H (2005b) Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 6:591-602. (Pubitemid 41059334)
28. Löscher W and Potschka H (2005c) Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 76:22-76. (Pubitemid 41033402)
29. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
30. Morgan ET, Goralski KB, Piquette-Miller M, Renton KW, Robertson GR, Chaluvadi MR, Charles KA, Clarke SJ, Kacevska M, Liddle C, et al. (2008) Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 36:205-216. (Pubitemid 351185732)
31. Mori S, Takanaga H, Ohtsuki S, Deguchi T, Kang YS, Hosoya K, and Terasaki T (2003) Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells. J Cereb Blood Flow Metab 23:432-440. (Pubitemid 36403025)
32. Mori S, Ohtsuki S, Takanaga H, Kikkawa T, Kang YS, and Terasaki T (2004) Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. J Neurochem 90:931-941. (Pubitemid 39099975)
33. Naud J, Michaud J, Boisvert C, Desbiens K, Leblond FA, Mitchell A, Jones C, Bonnardeaux A, and Pichette V (2007) Down-regulation of intestinal drug transporters in chronic renal failure in rats. J Pharmacol Exp Ther 320:978-985. (Pubitemid 46294060)
34. Naud J, Michaud J, Leblond FA, Lefrancois S, Bonnardeaux A, and Pichette V (2008) Effects of chronic renal failure on liver drug transporters. Drug Metab Dispos 36:124-128.
35. Naud J, Michaud J, Beauchemin S, Hébert MJ, Roger M, Lefrancois S, Leblond FA, and Pichette V (2011) Effects of chronic renal failure on kidney drug transporters and cytochrome P450 in rats. Drug Metab Dispos 39:1363-1369.
36. Nozaki Y, Kusuhara H, Kondo T, Hasegawa M, Shiroyanagi Y, Nakazawa H, Okano T, and Sugiyama Y (2007) Characterization of the uptake of organic anion transporter (OAT) 1 and OAT3 substrates by human kidney slices. J Pharmacol Exp Ther 321:362-369. (Pubitemid 46456974)
37. Oettinger CW, Bland LA, Oliver JC, Arduino MJ, McAllister SK, and Favero MS (1994) The effect of uremia on tumor necrosis factor-alpha release after an in vitro whole-blood endotoxin challenge. J Am Soc Nephrol 4:1890-1895. (Pubitemid 24976995)
38. Ohtsuki S and Terasaki T (2007) Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758. (Pubitemid 47206624)
39. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, and Terasaki T (2002) Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem 83:57-66.
40. Ose A, Ito M, Kusuhara H, Yamatsugu K, Kanai M, Shibasaki M, Hosokawa M, Schuetz JD, and Sugiyama Y (2009) Limited brain distribution of [3R,4R,5S]-4-acetamido-5-amino-3-(1- ethylpropoxy)-1-cyclohexene-1-carboxylate phosphate (Ro 64-0802), a pharmacologically active form of oseltamivir, by active efflux across the blood-brain barrier mediated by organic anion transporter 3 (Oat3/Slc22a8) and multidrug resistance-associated protein 4 (Mrp4/Abcc4). Drug Metab Dispos 37:315-321.
41. Ose A, Kusuhara H, Endo C, Tohyama K, Miyajima M, Kitamura S, and Sugiyama Y (2010) Functional characterization of mouse organic anion transporting peptide 1a4 in the uptake and efflux of drugs across the blood-brain barrier. Drug Metab Dispos 38:168-176.
42. Oswald S, Grube M, Siegmund W, and Kroemer HK (2007) Transporter-mediated uptake into cellular compartments. Xenobiotica 37:1171-1195. (Pubitemid 350035533)
43. Perrière N, Demeuse P, Garcia E, Regina A, Debray M, Andreux JP, Couvreur P, Scherrmann JM, Temsamani J, Couraud PO, et al. (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93:279-289. (Pubitemid 40547485)
44. Petrovic V, Teng S, and Piquette-Miller M (2007) Regulation of drug transporters during infection and inflammation. Mol Interv 7:99-111. (Pubitemid 46683180)
45. Poller B, Drewe J, Krähenbühl S, Huwyler J, and Gutmann H (2010) Regulation of BCRP (ABCG2) and P-glycoprotein (ABCB1) by cytokines in a model of the human blood-brain barrier. Cell Mol Neurobiol 30:63-70.
46. Ronaldson PT and Bendayan R (2006) HIV-1 viral envelope glycoprotein gp120 triggers an inflammatory response in cultured rat astrocytes and regulates the functional expression of P-glycoprotein. Mol Pharmacol 70:1087-1098. (Pubitemid 44268466)
47. Sun H, Huang Y, Frassetto L, and Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 32:1239-1246. (Pubitemid 39410907)
48. Sun H, Frassetto L, and Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1-11. (Pubitemid 41740811)
49. Sunder-Plassmann G, Kapiotis S, Gasche C, and Klaar U (1994) Functional characterization of cytokine autoantibodies in chronic renal failure patients. Kidney Int 45:1484-1488. (Pubitemid 24135037)
50. Tahara H, Shono M, Kusuhara H, Kinoshita H, Fuse E, Takadate A, Otagiri M, and Sugiyama Y (2005) Molecular cloning and functional analyses of OAT1 and OAT3 from cynomolgus monkey kidney. Pharm Res 22:647-660. (Pubitemid 40603263)
51. Ueo H, Motohashi H, Katsura T, and Inui K (2005) Human organic anion transporter hOAT3 is a potent transporter of cephalosporin antibiotics, in comparison with hOAT1. Biochem Pharmacol 70:1104-1113. (Pubitemid 41262086)
52. von Wedel-Parlow M, Wölte P, and Galla HJ (2009) Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem 111:111-118.
53. Zhao YL, Du J, Kanazawa H, Sugawara A, Takagi K, Kitaichi K, Tatsumi Y, Takagi K, and Hasegawa T (2002) Effect of endotoxin on doxorubicin transport across blood-brain barrier and P-glycoprotein function in mice. Eur J Pharmacol 445:115-123. (Pubitemid 34628440)
54. Ziesche R, Roth M, Papakonstantinou E, Nauck M, Hörl WH, Kashgarian M, and Block LH (1994) A granulocyte inhibitory protein overexpressed in chronic renal disease regulates expression of interleukin 6 and interleukin 8. Proc Natl Acad Sci USA 91:301-305. (Pubitemid 24018692)